Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
about
Bevacizumab for glioblastomaA prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation.New Directions in Anti-Angiogenic Therapy for Glioblastoma.Angiogenesis inhibitors in tackling recurrent glioblastoma.Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials.Is there a role for bevacizumab in the treatment of glioblastoma?Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma.Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET).Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial.Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature.A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma.Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 T-lymphocyte countsTherapeutic Immunization against Glioblastoma
P2860
Q26776307-57CFAA7E-C6DF-4EED-8C18-73AE2F0C5F9CQ36893250-FA765477-FB95-4BD1-AF2D-699B215987BCQ39022941-EBAB4294-D5A8-4E67-AB4B-449B256B3D86Q39259089-06C19E51-5F5F-4B32-9E1E-42F315143536Q39436924-7987C9B1-7A3D-4F2E-A4E3-F3CF06DA3A0DQ41342037-4CDBFCE4-02E5-47B0-9ED1-762701ACE07EQ42227769-5347EE20-F832-41AE-ABAE-7175653E970DQ48113265-AB820139-CFDF-4855-A139-922405C430C5Q48149391-A87D8944-A4EC-44E0-BA4F-0EB508AC7ED1Q48175331-2A22547F-7D72-4A28-9263-E36D7881DE01Q48345799-CAE13B06-2886-48D2-A13B-620B0CE1B8F6Q49635346-FE509663-C584-4CA4-8457-0FAE3AB80F67Q55001435-9636F4AA-3A0E-4FD1-B31D-BB7CDC6A9141Q58692202-9FF2FF72-BE65-457E-8C5F-D5BAB9831E65Q58700123-E82BD4C6-4338-4131-ACE6-19268E7FEF90
P2860
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
@ast
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
@en
type
label
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
@ast
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
@en
prefLabel
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
@ast
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
@en
P2093
P2860
P356
P1433
P1476
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
@en
P2093
Ann Livingstone
Anna K Nowak
CABARET/COGNO investigators
Elizabeth H Barnes
Elizabeth J Hovey
Helen Wheeler
John Simes
Kate Sawkins
Kathryn M Field
P2860
P304
P356
10.1093/NEUONC/NOV104
P50
P577
2015-06-30T00:00:00Z